Gao Lei, Chen Ruo-Wen, Williams John P, Li Tong, Han Wei-Jiang, Zhao Qian-Nan, Wang Yong, An Jian-Xiong
Department of Anesthesiology, Weifang Medical University, Weifang City 261000, Shangdong, People's Republic of China.
Department of Anesthesiology, Pain and Sleep Medicine, Aviation General Hospital of China Medical University and Beijing Institute of Translational Medicine, Chinese Academy of Sciences, Beijing, 100012, People's Republic of China.
J Pain Res. 2020 May 4;13:927-936. doi: 10.2147/JPR.S232081. eCollection 2020.
Ozone injection around Gasserian ganglion (OIAGG) has been reported to be an effective treatment for trigeminal neuralgia (TN); however, there remain areas for improvement. To overcome one of these limitations, a multicenter examination of application would be extremely helpful.
The goal of this report was to assess the efficacy of OIAGG for refractory TN across multiple centers and to explore factors predictive of successful treatment.
A multicenter, retrospective study.
The study was conducted across 3 pain centers across China.
A total of 103 subjects from 3 pain centers were enrolled in the study. An ozone-oxygen mixture gas at a concentration of 30 µg/mL was injected into the area around the Gasserian ganglion performed under C-arm X-ray guidance. Primary outcome measures included a pain assessment using a visual analog scale (VAS) and the Barrow Neurological Institute (BNI) pain intensity scale. Clinical assessment of patients for these outcome measures was performed at pretreatment, post-treatment, 6 months, 1 year and 2 years after the OIAGG.
Successful pain relief was defined as a score within BNI grades I-IIIa. The pain relief rates at post-treatment, 6 months, 1 year and 2 years after the procedure were 88.35%, 86.87%, 84.46% and 83.30%, respectively. The VAS at each observation time point was significantly different from the preoperative levels (P<0.05). Logistic regression analysis showed that previous nerve damage had a significant effect on the treatment results. No significant complications or side effects were found during or after treatment.
This multicenter research confirms our previous single center results that OIAGG is both effective and safe for patients with TN.
据报道，半月神经节周围臭氧注射（OIAGG）是治疗三叉神经痛（TN）的一种有效方法；然而，仍有改进的空间。为克服这些局限性之一，进行多中心应用研究将非常有帮助。
本报告的目的是评估多中心OIAGG治疗难治性TN的疗效，并探索预测治疗成功的因素。
一项多中心回顾性研究。
该研究在中国的3个疼痛中心进行。
来自3个疼痛中心的103名受试者纳入研究。在C形臂X线引导下，将浓度为30μg/mL的臭氧 - 氧气混合气体注入半月神经节周围区域。主要结局指标包括使用视觉模拟量表（VAS）和巴罗神经学研究所（BNI）疼痛强度量表进行疼痛评估。在OIAGG治疗前、治疗后、6个月、1年和2年对患者进行这些结局指标的临床评估。
成功缓解疼痛定义为BNI分级为I - IIIa级。术后、术后6个月、1年和2年的疼痛缓解率分别为88.35%、86.87%、84.46%和83.30%。各观察时间点的VAS与术前水平相比有显著差异（P<0.05）。逻辑回归分析表明，既往神经损伤对治疗结果有显著影响。治疗期间及治疗后未发现明显并发症或副作用。
这项多中心研究证实了我们之前单中心的结果，即OIAGG对TN患者既有效又安全。
